A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs RRx 001 (Primary)
- Indications Stomatitis
- Focus Therapeutic Use
- Acronyms PREVLAR
- Sponsors EpicentRx
- 22 Nov 2019 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020.
- 09 Oct 2019 Planned primary completion date changed from 1 Jun 2019 to 31 Oct 2019.
- 09 Oct 2019 Status changed from recruiting to active, no longer recruiting.